John Newman continues to expect NDA in 2018 for bremelanotide, while pipeline moves forward.
CFO Paul Herendeen sought out to convince investors to put their money into the long game.
Ram Selvaraju slashes his target to $8 on slower Trulance ramp.
Could Versartis recover after today’s big decline?
A ‘game over’ for Versartis’ somavaratan; A powerful boost for Ascendis’ TC-hGH.
Intercept Sank 40% in September following Dear Doctor and FDA warning letters; Ritu Baral weighs in.
Analyst praises Alnylam’s patisiran as best-in-class, even more confident in its safety and tolerability profile.
Analyst initiates a bullish perspective on Dynavax, ascribing a probability of 95% approval for its lead asset.
Analyst says share weakness does not stem from encouraging news, but points to other underlying concerns.
Supernus investors are running for the hills, but analyst sees elimination of 18 mg dose as a good move.